Omicia raises $23M in Series B

What does Omicia do/

Omicia, is a leading provider of clinical genome interpretation and reporting software. The company operates a database which provides info about genetic variations for clinicians and researchers. The company is unlocking customized medicine through data translation derived from the whole genome sequencing into actionable info for clinicians and researchers. The company maintains a comprehensive database of info about gene variations related to health conditions and is pioneering new informative approaches which will boost the power of preventive and predictive medicine. The company’s software provides leading health care system stake holders with accurate, fast and scalable NXS- next generation sequence interpretation and reporting capabilities for driving improved clinical outcomes. Also the company provides customer a choice of scaling production in HIPAA-compliant, cloud-enabled environment.
How much Omicia was funded?

Omicia raised $23M in Series B on June 8, 2016 from Buchanan Investments, ARTIS Ventures, Acadia Woods Partners, LDV Partners, Ping An Ventures,  UPMC and Roche Venture Fund.

Previous funding

$6.8M in Series A on January 6, 2014 from Bay City Capital, Acadia Woods Partners, Casdin Capital, ARTIS Ventures and Buchanan Investments.

What is next for Omicia?

The company plans on using the latest funding raised for fueling acceleration in product development for expanding its sales, marketing, sales support and operations. Also the company plans on extending variations of its flagship product OpalTM clinical platform for using in new verticals  including clinical trial support, life science research, consumer applications and population health management; and new places on the globe.

More about Omicia

Omicia was founded in 2009 by Martin G. Reese and Edward S. Kiruluta. It has its headquarters in Oakland, CA. The company delivers a software platform which helps analysis, interpretation and reporting of genomic data for expediting diagnosis and improving medical outcomes. The company’s products are in use in over 500 world class clinical and academic institutions around the globe.